Market Size of Bioprocess Analyzers Industry
Study Period | 2019 - 2029 |
Market Size (2024) | USD 2.00 Billion |
Market Size (2029) | USD 4.17 Billion |
CAGR (2024 - 2029) | 15.80 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Bioprocess Analyzers Market Analysis
The Bioprocess Analyzers Market size is estimated at USD 2 billion in 2024, and is expected to reach USD 4.17 billion by 2029, growing at a CAGR of 15.80% during the forecast period (2024-2029).
The pandemic had an effect on the market studied. Factors such as high titer, constant product quality, the robustness of the process, fast turnaround times, and scalability are some of the reasons why bioprocess containers are being used in vaccine production. There are many companies whose products are being used for COVID-19 vaccine research. With the large-scale vaccination programs around the world and the new investments in the biopharmaceutical industry, the market studied is expected to regain its potential over the years.
The major factors attributed to the growth of the market are the growing interest in the development of advanced medicines and vaccines and the increasing demand for biologics. These factors are expected to increase the market's growth. The rising geriatric population is susceptible to chronic diseases, which is increasing the demand for biologics. Cardiovascular disease is one of the leading causes of death globally, in which myocardial infarction (MI) is a major event. According to the article published in March 2021 by the National Library of Medicine, current therapies do not adequately address the multiple dysregulated systems following MI. The research to develop drug delivery systems for biologics is expected to increase over the forecast period, positively impacting the growth of the market. The increasing investments by the major market players in the development of biologics are driving the market's growth. In 2022, Aurobindo Pharma (CuraTeQ Biologics) planned to invest around INR 300 crore in capacity expansion of biologics manufacturing facilities, and this facility is likely to be fully operational by 2026. Furthermore, biologics is efficient in treating rheumatoid arthritis and Crohn's disease, which may lead to the growth of bioprocess analyzers in the production process of biological products. Thus, the aforementioned factors are expected to increase the market's growth during the forecast period.
However, difficulties faced during the upstream and downstream process due to the small-sized bioprocessing equipment and the relatively high cost of the raw materials are constraints to the growth of the market.